| 8.54 -0.64 (-6.97%) | 09-09 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 423.12 | 1-year : | 446.18 |
| Resists | First : | 362.26 | Second : | 382.01 |
| Pivot price | 361.13  |
|||
| Supports | First : | 330.32 | Second : | 274.82 |
| MAs | MA(5) : | 353.44 |
MA(20) : | 363.52 |
| MA(100) : | 320.45 |
MA(250) : | 279.37 |
|
| MACD | MACD : | -0.4 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 27 |
D(3) : | 29.4 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 382.01 | Low : | 205.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CAT ] has closed above bottom band by 8.1%. Bollinger Bands are 24.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 342.09 - 343.84 | 343.84 - 345.18 |
| Low: | 326.3 - 328.11 | 328.11 - 329.5 |
| Close: | 335.09 - 338.17 | 338.17 - 340.54 |
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
Wed, 08 Sep 2021
Catabasis Renames As Astria Therapeutics With New Disease Focus - Yahoo Finance
Wed, 08 Sep 2021
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus - Business Wire
Mon, 01 Feb 2021
Catabasis Pharmaceuticals Acquires Quellis Biosciences - FinSMEs
Fri, 29 Jan 2021
CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today - InvestorPlace
Thu, 10 Dec 2020
Ovid Therapeutics Inc. (NASDAQ:OVID) Halts NEPTUNE Study Of OV101 After Failing To Achieve Primary Endpoint - BP Journal
Thu, 29 Oct 2020
Solid makes Duchenne deal, Catabasis' trial failure - Boston Business Journal - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 499 (M) |
| Shares Float | 498 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 72.4 (%) |
| Shares Short | 13,060 (K) |
| Shares Short P.Month | 13,910 (K) |
| EPS | 20.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 39.04 |
| Profit Margin | 15.4 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | 10 % |
| Return on Equity (ttm) | 58.3 % |
| Qtrly Rev. Growth | 2.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 134.28 |
| EBITDA (p.s.) | 31.51 |
| Qtrly Earnings Growth | 89.3 % |
| Operating Cash Flow | 12,890 (M) |
| Levered Free Cash Flow | 8,490 (M) |
| PE Ratio | 17.14 |
| PEG Ratio | 1.3 |
| Price to Book value | 8.83 |
| Price to Sales | 2.56 |
| Price to Cash Flow | 13.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|